Cofttek holdings limited


Mubritinib (TAK 165) (366017-09-6)

Mubritinib also known as TAK-165, is a protein kinase inhibitor which was under development by Takeda for the treatment of cancer. It completed phase I clinical trials (may be discontinued since 2008).

Not Intended for Therapeutic Use. For research use only.

CAS: 366017-09-6 Category

Mubritinib (TAK 165) (366017-09-6) Description:

Mubritinib(TAK 165) has been used in trials studying the treatment of Lung Neoplasm, Renal Neoplasm, Breast Neoplasm, Ovarian Neoplasm, and Pancreatic Neoplasm. Mubritinib(TAK 165) is a potent EGFR, HER2 and p34cdc2 inhibitor with IC50 of 6 nM and 0.2 µM, respectively. Mubritinib(TAK 165) also inhibits p33cdk2 and p33cdk5. Mubritinib(TAK 165) displays > 4000-fold selectivity over EGFR, FGFR, PDGFR, JAK1 and Src. Mubritinib(TAK 165) exhibits potent antiproliferative effects in ErbB2-overexpressing cancer cell lines (IC50 = 5 nM in BT474 breast cancer cells) and significantly inhibits bladder, breast and prostate cancer xenograft growth in vivo.

Mubritinib (TAK 165) (366017-09-6) Specifications:

Product Name Mubritinib
Synonym TAK165, TAK-165, TAK 165,
Chemical Name (E)-4-((4-(4-(1H-1,2,3-triazol-1-yl)butyl)phenoxy)methyl)-2-(4-(trifluoromethyl)styryl)oxazole
Purity ≥98% (HPLC)
CAS Number 366017-09-6
Molecular Formula C25H23F3N4O2
Molecular Weight 468.48 g/mol
Monoisotopic Mass 468.177 g/mol
MDL number MFCD09954135
InChi Code InChI=1S/C25H23F3N4O2/c26-25(27,28)21-9-4-20(5-10-21)8-13-24-30-22(18-34-24)17-33-23-11-6-19(7-12-23)3-1-2-15-32-16-14-29-31-32/h4-14,16,18H,1-3,15,17H2/b13-8+
Form powder
Color white to beige
Solubility  Water Solubility 0.0124 mg/mL
Storage Temp.  -20°C
Shelf life >2 years if stored properly
Handling Protect from air and moisture, dark, dry
Application protein kinase inhibitor


RIDADR NONH for all modes of transport